Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
14 June 2024 - 10:00PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by dysregulated aldosterone, today announced that Alexander
M. Gold, M.D. has been appointed to the Company's Board of
Directors (the Board), effective June 13, 2024.
“We are delighted to welcome Alex to our Board of Directors as
we advance the late-stage clinical development of lorundrostat for
the treatment of hypertension and related cardiorenal metabolic
disorders,” stated Jon Congleton, Chief Executive Officer of
Mineralys. “As a cardiologist and accomplished biopharmaceutical
clinical development executive, Alex brings tremendous experience
driving value for biopharmaceutical companies. We believe Alex’s
track record of successful pipeline development, regulatory
approvals, and joint ventures will make him be a valuable director
and resource for the Company’s team.”
“I am honored to join the Mineralys Board of Directors,” stated
Dr. Gold. “I look forward to working with the Company’s executive
team and fellow Board members to advance the treatment of
cardiorenal metabolic disorders. There is significant potential
with lorundrostat in offering a targeted treatment approach for
hypertension and other diseases driven by dysregulated
aldosterone.”
Dr. Gold is a cardiologist with more than 20 years of experience
leading the development, approval, and commercialization of new
therapies. He has held executive positions at several
biopharmaceutical companies that targeted numerous therapeutic
areas, including cardiometabolic, renal, and inflammation.
Currently, Dr. Gold is the Chief Medical Officer of a
clinical-stage biotech company. Prior to his current role, he held
the role of Head Medical Officer at Sanifit-CSL. He originally
joined as Chief Medical Officer and President of Sanifit Inc. in
2017, which was then acquired by Vifor Pharma in January 2022 and
subsequently by CSL Ltd. in August 2022. Prior to Sanifit, Dr. Gold
held the role of Senior Vice President and Head of Clinical
Development at Portola Pharmaceuticals. Prior to Portola
Pharmaceuticals, Dr. Gold was Head of Clinical Development at Reata
Pharmaceuticals. For 11 years he held multiple leadership positions
at AstraZeneca, including the Executive Director and Development
Leader for BRILINTA, CRESTOR and ONGLYZA. Dr. Gold is currently an
Adjunct Professor at Stanford University School of Medicine.
Dr. Gold completed his residency in internal medicine and
fellowship in cardiology at the Beth Israel Deaconess Medical
Center / Harvard Medical School in Boston and conducted
translational and clinical research as a fellow in cardiovascular
research at the Harvard Clinical Research Institute and was a
Scholar in Clinical Science. Dr. Gold received his M.D. from
Harvard Medical School and his B.A in Biology from Brandeis
University.
In addition, the Company announced the resignation of Olivier
Litzka, Ph.D. from its Board, effective June 13,
2024.
Dr. Litzka stated: “It was an honor for me to serve on the
Mineralys Board since the Company’s final private financing round
prior to the initial public offering. The Company has shown
tremendous progress, which is due to its exceptionally talented and
hard working team. As a venture capital investor, I’ve decided to
step down in order to make room for new, well-suited board members
like Alex Gold to support the Company going forward. I wish
Mineralys all the best on its path forward.”
“The Board and I would like to express our collective gratitude
to Olivier for his contributions and dedication to the Board. We
wish him future success as he turns his attention to other venture
investments at Andera Partners,” stated Mr. Congleton.
About LorundrostatLorundrostat is a
proprietary, orally administered, highly selective aldosterone
synthase inhibitor being developed for the treatment of
uncontrolled hypertension and CKD. Lorundrostat was designed to
reduce aldosterone levels by inhibiting CYP11B2, the enzyme
responsible for its production. Lorundrostat has 374-fold
selectivity for aldosterone-synthase inhibition versus
cortisol-synthase inhibition in vitro, an observed half-life of
10-12 hours and demonstrated approximately a 70% reduction in
plasma aldosterone concentration in hypertensive subjects.
In a Phase 2, proof-of-concept trial (Target-HTN) in
uncontrolled or resistant hypertensive subjects, once-daily
lorundrostat demonstrated clinically meaningful blood pressure
reduction in individuals with uncontrolled hypertension, in both
automated office blood pressure measurement and 24-hour ambulatory
blood pressure monitoring. Adverse events observed were a modest
increase in serum potassium, decrease in estimated glomerular
filtration rate, urinary tract infection and hypertension with one
serious adverse event possibly related to study drug being
hyponatremia.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, CKD and other
diseases driven by dysregulated aldosterone. Its initial product
candidate, lorundrostat, is a proprietary, orally administered,
highly selective aldosterone synthase inhibitor that Mineralys
Therapeutics is developing for cardiorenal conditions affected by
dysregulated aldosterone, including hypertension and CKD. Mineralys
is based in Radnor, Pennsylvania, and was founded by Catalys
Pacific. For more information, please visit
https://mineralystx.com. Follow Mineralys on LinkedIn and
Twitter.
Forward Looking Statements
Mineralys Therapeutics cautions you that statements contained in
this press release regarding matters that are not historical facts
are forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to, statements regarding: the potential therapeutic
benefits of lorundrostat. Actual results may differ from those set
forth in this press release due to the risks and uncertainties
inherent in our business, including, without limitation: our future
performance is dependent entirely on the success of lorundrostat;
potential delays in the commencement, enrollment and completion of
clinical trials and nonclinical studies; later developments with
the FDA may be inconsistent with the feedback from the completed
end of Phase 2 meeting, including whether the proposed pivotal
program will support registration of lorundrostat which is a review
issue with the FDA upon submission of an NDA; our dependence on
third parties in connection with manufacturing, research and
clinical and nonclinical testing; unexpected adverse side effects
or inadequate efficacy of lorundrostat that may limit its
development, regulatory approval and/or commercialization;
unfavorable results from clinical trials and nonclinical studies;
results of prior clinical trials and studies of lorundrostat are
not necessarily predictive of future results; our reliance on our
exclusive license with Mitsubishi Tanabe Pharma to provide us with
intellectual property rights to develop and commercialize
lorundrostat; and other risks described in our filings with the
Securities and Exchange Commission (SEC), including under the
heading “Risk Factors” in our annual report on Form 10-K, and any
subsequent filings with the SEC. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and we undertake no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary
statement, which is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Contact:
Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Sep 2023 to Sep 2024